Cendakimab

About Bristol Myers Squibb

Bristol Myers Squibb (BMS) is a premier global biopharmaceutical company with a mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. The company has achieved landmark status through transformative therapies like Opdivo (nivolumab) and Yervoy in immuno-oncology, and maintains a robust pipeline fueled by a strategy of causal human biology and modality matching. BMS's core strategy involves a disciplined R&D framework, strategic business development to bolster its pipeline, and a focus on expanding the reach of its cell therapy and novel oncology assets while navigating near-term patent expirations.

Therapeutic Areas

Other Eosinophilic Esophagitis (EoE) Drugs